Proposed cut-off value of the intrahepatic lipid content for metabolically normal persons assessed by proton magnetic resonance spectroscopy in a Japanese population

Diabetes Research and Clinical Practice

Volumn 119, Issue , 2016, Pages 75-82

  Matsubara, Fumiaki ^a,b   Nagai, Yoshio ^a,b   Tsukiyama, Hidekazu ^a,b   Shimizu, Hiroyuki ^b   Yamanouchi, Eigoro ^b   Iwamoto, Teruaki ^b   Sada, Yukiyoshi ^a   Kato, Hiroyuki ^a   Ohta, Akio ^a   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b International University of Health and Welfare Hospital   (Japan)

Author keywords

Intrahepatic lipid content; Metabolic syndrome; Nonalcoholic fatty liver disease; Proton magnetic resonance spectroscopy

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAHEPATIC LIPID; JAPANESE (PEOPLE); LIPID LIVER LEVEL; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; FATTY LIVER; JAPAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; FATTY LIVER; FEMALE; HUMANS; JAPAN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RISK FACTORS; YOUNG ADULT;

EID: 84980324648     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.07.005     Document Type: Article

References (45)

1. [1] O'Neill, S., O'Driscoll, L., Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16:1 (2015), 1–12.
2. [2] Sookoian, S., Pirola, C.J., Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep 13:2 (2011), 149–157.
3. [3] Klein, B.E., Klein, R., Lee, K.E., Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25:10 (2002), 1790–1794.
4. [4] Deedwania, P.C., Gupta, R., Management issues in the metabolic syndrome. J Assoc Physicians India 54 (2006), 797–810.
5. [5] Blüher, M., Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117:6 (2009), 241–250.
6. [6] Cigolini, M., Targher, G., Agostino, G., Tonoli, M., Muggeo, M., De Sandre, G., et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men – role of the metabolic syndrome. Thromb Haemost 76:1 (1996), 69–73.
7. [7] Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:8 (2001), 1844–1850.
8. [8] Marchesini, G., Brizi, M., Morselli-Labate, A.M., Bianchi, G., Bugianesi, E., McCullough, A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:5 (1995), 450–455.
9. [9] Seppälä-Lindroos, A., Vehkavaara, S., Häkkinen, A.M., Goto, T., Westerbacka, J., Sovijärvi, A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:7 (2002), 3023–3028.
10. [10] Tiikkainen, M., Tamminen, M., Häkkinen, A.M., Bergholm, R., Vehkavaara, S., Halavaara, J., et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 10:9 (2002), 859–867.
11. [11] Stefan, N., Kantartzis, K., Machann, J., Schick, F., Thamer, C., Ritting, K., et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:15 (2008), 1609–1616.
12. [12] Fabbrini, E., Magkos, F., Mohammed, B.S., Pietka, T., Abumrad, N.A., Patterson, B.W., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106:36 (2009), 15430–15435.
13. [13] Sada, Y., Katabami, T., Asai, S., Sato, T., Furukawa, K., Ishii, S., et al. Intrahepatic lipid content is linked to insulin resistance in obese subjects. Obes Res Clin Pract 5:2 (2011), e79–e156.
14. [14] Fabbrini, E., Sullivan, S., Klein, S., Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:2 (2010), 679–689.
15. [15] Magkos, F., Su, X., Bradley, D., Fabbrini, E., Conte, C., Eaqon, J.C., et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142:7 (2012), 1444–1446.
16. [16] Stefan, N., Schick, F., Häring, H.U., Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371:23 (2014), 2236–2237.
17. [17] Stefan, N., Häring, H.U., Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19 (2013), 394–395.
18. [18] Stefan, N., Häring, H.U., The role of hepatokines in metabolism. Nat Rev Endocrinol 9:3 (2013), 144–152.
19. [19] Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:2 (2005), E462–8.
20. [20] Petersen, K.F., Dufour, S., Feng, J., Befroy, D., Dziura, J., Dalla Man, C., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 103:48 (2006), 18273–18277.
21. [21] Browning, J.D., Szczpaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:6 (2004), 1387–1395.
22. [22] Wong, V.W., Wong, G.L., Yeung, D.K., Lau, T.K., Chan, C.K., Chim, A.M., et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 62:1 (2015), 182–189.
23. [23] Tsutsutmi, M., The history of the diagnostic criteria for alcoholic liver disease and current status of alcoholic liver disease in Japan. Nippon Shokakibyo Gakkai Zasshi 109 (2012), 1509–1517 (in Japanese).
24. [24] Farrell, G.C., Chitturi, S., Lau, G.K., Sollano, J.D., Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 22:6 (2007), 775–777.
25. [25] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Tumer, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:7 (1985), 412–419.
26. [26] Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. International Diabetes Federation Task Force on Epidemiology and Prevention National Heart, Lung, and Blood Institute American Heart Association, World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:16 (2009), 1640–1645.
27. [27] Sato, T., Katabami, T., Furukawa, K., Narimatsu, H., Hashimoto, T., Nakajima, Y., et al. Intracellular lipid content of liver and skeletal muscle in patients with adult growth hormone deficiency without diabetes mellitus. Obes Res Clin Pract 6:4 (2012), e263–346.
28. [28] Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract 109:1 (2015), 199–205.
29. [29] Kato, K., Takamura, T., Takeshita, Y., Ryu, Y., Misu, H., Ota, T., et al. Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. PLoS One, 9(3), 2014, e92170.
30. [30] Wei, J.L., Leung, J.C., Loong, T.C., Wong, G.L., Yeung, D.K., Chan, R.S., et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 110:9 (2015), 1306–1314.
31. [31] Kwiterovich, P.O. Jr., Sloan, H.R., Fredrickson, D.S., Glycolipids and other lipid constituents of normal human liver. J Lipid Res 11:4 (1970), 322–330.
32. [32] Furukawa, K., Katabami, T., Nakajima, Y., Sato, T., Kato, H., Koganei, R., et al. Evaluation of whole-abdominal fat volume by 700-slice CT scanning and comparison with the umbilical fat area anthropometric indices. Obes Res Clin Pract 4:2 (2010), e83–e162.
33. [33] Wildman, R.P., Muntner, P., Reynolds, K., McGinn, A.P., Rajpathak, S., Wylie-Rosett, J., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168:15 (2008), 1617–1624.
34. [34] Primeau, V., Coderre, L., Karelis, A.D., Brochu, M., Lavoie, M.E., Messier, V., et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 35:7 (2011), 971–981.
35. [35] Müller, M.J., Lagerpusch, M., Enderle, J., Schautz, B., Heller, M., Bosy-Westphal, A., Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev 13 (2012), 6–13.
36. [36] Fabbrini, E., Yoshino, J., Yoshino, M., Magkos, F., Tiemann Luecking, C., Samovski, D., et al. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest 125:2 (2015), 787–795.
37. [37] Lee, S.S., Park, S.H., Kim, H.J., Kim, S.Y., Kim, M.Y., Kim, D.Y., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52:4 (2010), 579–585.
38. [38] Tang, A., Tan, J., Sun, M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267:2 (2013), 422–431.
39. [39] Tang, A., Desai, A., Hamilton, G., Wolfson, T., Gamst, A., Lam, J., et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274:2 (2015), 416–425.
40. [40] Gao, B., Bataller, R., Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141:5 (2011), 1572–1585.
41. [41] Gunji, T., Matsuhashi, N., Sato, H., Fujibayashi, K., Okumura, M., Sasabe, N., et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 104:9 (2009), 2189–2195.
42. [42] Kwon, H.J., Won, Y.S., Park, O., Chang, B., Duryee, M.J., Thiele, G.E., et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 60:1 (2014), 146–157.
43. [43] Takeshita, T., Morimoto, K., Mao, X., Hashimoto, T., Furuyama, J., Characterization of the three genotypes of low Km aldehyde dehydrogenase in a Japanese population. Hum Genet 94:3 (1994), 217–223.
44. [44] Hayashi, P.H., Harrison, S.A., Torgerson, S., Perez, T.A., Nochajski, T., Russell, M., Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol 99:1 (2004), 76–81.
45. 1H MR spectrum. NMR Biomed 24:7 (2011), 784–790.